Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis

• DOI: 10.1523/jneurosci.15-01-00821.1995
• Publication Date: 2018-04-02T18:40:37Z
• Authors: SL Dewey; GS Smith; J Logan; D Alexoff; YS Ding; P King; N Pappas; JD Brodie; CR Ashby
• Keywords: Microdialysis; PET Imaging

Positron emission tomography and in vivo microdialysis were used to study serotonin's role modulating striatal dopamine. Serial PET studies performed adult female baboons at baseline following drug treatment, using the dopamine (D2) selective radiotracer, 11C-raclopride. The serotonergic system was manipulated by administration of 5-HT reuptake inhibitor, citalopram, or (5-HT2) receptor blockade (using altanserin, a 5-HT2 antagonist). 11C-Raclopride time-activity data from striatum cerebellum combined with plasma arterial input functions analyzed calculating distribution volume as described previously (Logan et al., 1990). Additionally, awake freely moving rats similar pharmacologic challenges plus SR 46349B, new highly antagonist. Altanserin 46349B increased extracellular concentrations (35% 910%, respectively) while altanserin decreased 11C-raclopride binding (37%). Citalopram, however, (50%) (33%). These demonstrate that 5-HT-selective drugs produce changes can be measured noninvasively PET. Furthermore, obtained anesthetized is consistent rats. Finally, these have implications for understanding therapeutic efficacy atypical neuroleptics their utility treating schizophrenia affective disorders.